UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

Campone, Mario; Lacroix-Triki, Magali; Roca, Lise; Spielmann, Marc; Wildiers, Hans; Cottu, Paul; Kerbrat, Pierre; Levy, Christelle; Desmoulins, Isabelle; Bachelot, Thomas; Winston, Tan; Eymard, Jean-Christophe; Uwer, Lionel; Duhoux, Francois P; Verhoeven, Didier; Jaubert, Dominique; Coeffic, David; Orfeuvre, Hubert; Canon, Jean Luc; Asselain, Bernard; Martin, Anne-Laure; Lemonnier, Jerome; Roché, Henri

Campone, Mario; Lacroix-Triki, Magali; Roca, Lise; Spielmann, Marc; Wildiers, Hans; Cottu, Paul; Kerbrat, Pierre; Levy, Christelle; Desmoulins, Isabelle; Bachelot, Thomas; Winston, Tan; Eymard, Jean-Christophe; Uwer, Lionel; Duhoux, Francois P; Verhoeven, Didier; Jaubert, Dominique; Coeffic, David; Orfeuvre, Hubert; Canon, Jean Luc; Asselain, Bernard; Martin, Anne-Laure; Lemonnier, Jerome; Roché, Henri.

Afiliação

Campone M; ICO René Gauducheau, Saint-Herblain, France. Electronic address: Mario.campone@ico.unicancer.fr.
Lacroix-Triki M; Gustave Roussy, Villejuif, France.
Roca L; Centre Val D'Aurelle, Montpellier, France.
Spielmann M; Gustave Roussy, Villejuif, France.
Wildiers H; University Hospitals Leuven and KULeuven, Leuven, Belgium.
Cottu P; Institut Curie, Paris, France.
Kerbrat P; Centre Eugène Marquis, Rennes, France.
Levy C; Centre François Baclesse, Caen, France.
Desmoulins I; Centre Georges-François Leclerc, Dijon, France.
Bachelot T; Centre Léon Bérard, Lyon, France.
Winston T; Mayo Clinic, Jacksonville, FL, USA.
Eymard JC; Institut Jean Godinot, Reims, France.
Uwer L; Centre Alexis Vautrin, Nancy, France.
Duhoux FP; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Verhoeven D; University of AntwerpAZ, Belgium.
Jaubert D; Clinique Tivoli, Bordeaux, France.
Coeffic D; Polyclinique de Courlancy, Reims, France.
Orfeuvre H; CH de Fleyriat, Bourg en Bresse, France.
Canon JL; Grand Hopital de Charleroi, Charleroi, Belgium.
Asselain B; Institut Curie, Paris, France.
Martin AL; R&D UNICANCER, UCBG, Paris, France.
Lemonnier J; R&D UNICANCER, UCBG, Paris, France.
Roché H; Institut Claudius Regaud, IUCT Oncopole, Toulouse, France.

Eur J Cancer ; 103: 184-194, 2018 11.

Article em En | MEDLINE | ID: mdl-30267987

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Quimioterapia Adjuvante/métodos; Ciclofosfamida/uso terapêutico; Docetaxel/uso terapêutico; Epirubicina/uso terapêutico; Epotilonas/uso terapêutico; Fluoruracila/uso terapêutico; Adulto; Idoso; Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia; Neoplasias da Mama/patologia; Ciclofosfamida/farmacologia; Docetaxel/farmacologia; Epirubicina/farmacologia; Epotilonas/farmacologia; Feminino; Fluoruracila/farmacologia; Humanos; Pessoa de Meia-Idade; Estadiamento de Neoplasias; Análise de Sobrevida; Adulto Jovem

Palavras-chave

Adjuvant chemotherapy; Docetaxel; Early breast cancer; Ixabepilone; Poor prognosis breast cancer; Triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Epirubicina / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Ciclofosfamida / Epotilonas / Fluoruracila / Docetaxel Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google